Brind.

Phio Pharmaceuticals Corp. is developing therapeutics for cancer using INTASYL technology.

Steady: 0 in the last 7 days Updated oct 13

The latest in this situation

  1. PH-762 development advances following a successful manufacturing milestone.

How it started

1 report, 1 independent, last reported Jul 26. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Phio Pharmaceuticals Corp. is developing therapeutics for cancer using INTASYL technology.

Who's involved

What this event is mainly about
Cancer

How it developed

Newest first. Tap a step to see who reported it.
  1. Phio Pharmaceuticals Corp., a U.S. manufacturer, provides drug substance development services.Sub-event
  2. Phio Pharmaceuticals Corp. announced development of cancer therapeutics using INTASYL technology.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • NewsfilePhio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4